Prof. Dr. Falk Nimmerjahn

Lehrstuhl für Genetik

TUMOR-DERIVED GDF-15 PREVENTS THERAPY SUCCESS OF CHECKPOINT INHIBITORS BY BLOCKING T-LYMPHOCYTE RECRUITMENT (2021) Haake M, Schaefer T, Haack B, Vashist N, Genssler S, Harter P, Martens A, et al. Conference contribution There is strength in numbers: Quantitation of Fc gamma receptors on murine tissue-resident macrophages (2021) Vorsatz C, Friedrich N, Nimmerjahn F, Biburger M Journal article IN VIVO STUDIES OF IMMUNOMODULATORY A-CTLA-4 ANTIBODY IN A HUMANIZED MOUSE MODEL (2021) Reitinger C, Nimmerjahn F Conference contribution Targeting B cells in the pre-phase of systemic autoimmunity globally interferes with autoimmune pathology (2021) Werner A, Schäfer S, Zaytseva O, Albert H, Lux A, Kristic J, Pezer M, et al. Journal article A Phase II study to investigate the efficacy and safety of eltrombopag in combination with dexamethasone compared to dexamethasone as first-line treatment in adult patients with newly diagnosed primary ITP (XPAG-ITP) (2021) Binder M, Meyer O, Rummel M, Nimmerjahn F, Tesanovic T, Sauer T, Matzdorff A Conference contribution CD137 (4-1BB) triggering leads to metabolic and functional reprogramming of human monocytes/macrophages enhancing their tumoricidal activity (2021) Stoll A, Bruns H, Gamali S, Saul D, Fuchs M, Nimmerjahn F, Kunz M, et al. Conference contribution The Dual Targeting of FcRn and FcγRs via Monomeric Fc Fragments Results in Strong Inhibition of IgG-Dependent Autoimmune Pathologies (2021) Monnet C, Jacque E, de Romeuf C, Fontayne A, Abache T, Fournier N, Dupont G, et al. Journal article There Is strength in numbers - episode 2: a comprehensive quantitation of Fc gamma receptors on murine tissue-resident macrophages (2021) Friedrich N, Vorsatz C, Nimmerjahn F, Biburger M Conference contribution On the loss of inhibitory function due to FcgRIIB-I232T transmembrane polymorphism (2021) Pöhnl M, Nimmerjahn F, Böckmann R Conference contribution Fc-engineering significantly improves the recruitment of immune effector cells by anti-ICAM-1 antibody MSH-TP15 for myeloma therapy (2021) Klausz K, Cieker M, Kellner C, Roesner T, Otte A, Krohn S, Lux A, et al. Journal article